Literature DB >> 20671883

Rituximab for managing relapsing or refractory patients with idiopathic thrombotic thrombocytopenic purpura--haemolytic uraemic syndrome.

Domenica Caramazza1, Gerlando Quintini, Ignazio Abbene, Lucio Lo Coco, Alessandra Malato, Rosa Di Trapani, Giorgia Saccullo, Giuseppina Pizzo, Roberto Palazzolo, Rita Barone, Giuseppina Mazzola, Sergio Rizzo, Paolo Ragonese, Paolo Aridon, Vincenzo Abbadessa, Sergio Siragusa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20671883      PMCID： PMC2906191          DOI： 10.2450/2009.0101-09

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  54 in total

Review 1.  Thrombotic thrombocytopenic purpura: a paradigm shift?

Authors:  D B Cines; B A Konkle; M Furlan
Journal:  Thromb Haemost       Date:  2000-10       Impact factor: 5.249

Review 2.  Thrombotic thrombocytopenic purpura: new insights in disease pathogenesis and therapy.

Authors:  K V Lankford; C D Hillyer
Journal:  Transfus Med Rev       Date:  2000-07

3.  Potential strategies for the treatment of plasma exchange-resistant thrombotic thrombocytopenic purpura.

Authors:  G Quintini; V Barbera; E Iannitto; G Mariani
Journal:  Br J Haematol       Date:  2001-05       Impact factor: 6.998

4.  Improved survival with plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.

Authors:  P N Lara; T L Coe; H Zhou; L Fernando; P V Holland; T Wun
Journal:  Am J Med       Date:  1999-12       Impact factor: 4.965

5.  Factor V Leiden: a genetic risk factor for thrombotic microangiopathy in patients with normal von Willebrand factor-cleaving protease activity.

Authors:  Thomas J Raife; Steven R Lentz; Bonnie S Atkinson; Sara K Vesely; Martin J Hessner
Journal:  Blood       Date:  2002-01-15       Impact factor: 22.113

6.  Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders.

Authors:  J C Moore; C P Hayward; T E Warkentin; J G Kelton
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

7.  Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases.

Authors:  A Veyradier; B Obert; A Houllier; D Meyer; J P Girma
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

8.  Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic-uremic syndrome.

Authors:  M A Rizvi; S K Vesely; J N George; L Chandler; D Duvall; J W Smith; R O Gilcher
Journal:  Transfusion       Date:  2000-08       Impact factor: 3.157

9.  Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura.

Authors:  Valentina Bianchi; Rodolfo Robles; Lorenzo Alberio; Miha Furlan; Bernhard Lämmle
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

10.  Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity.

Authors:  Yoshitaka Mori; Hideo Wada; Esteban C Gabazza; Nobuyuki Minami; Tsutomu Nobori; Hiroshi Shiku; Hideo Yagi; Hiromichi Ishizashi; Masanori Matsumoto; Yoshihiro Fujimura
Journal:  Transfusion       Date:  2002-05       Impact factor: 3.157
View more
  8 in total

1.  Short- and long-term effects of rituximab for the treatment of thrombotic thrombocytopenic purpura: four case reports.

Authors:  Futoshi Iioka; Daiki Shimomura; Toru Ishii; Yoshitomo Maesako; Kazuhiro Ohgoe; Fumihiko Nakamura; Shuji Matsuo; Hitoshi Ohno
Journal:  Int J Hematol       Date:  2012-08-10       Impact factor: 2.490

Review 2.  How I treat refractory thrombotic thrombocytopenic purpura.

Authors:  Farzana A Sayani; Charles S Abrams
Journal:  Blood       Date:  2015-03-17       Impact factor: 22.113

3.  Reversible posterior leukoencephalopathy syndrome in a patient with thrombotic thrombocytopenic purpura.

Authors:  Paolo Aridon; Paolo Ragonese; Maria Antonietta Mazzola; Gerlando Quintini; Marianna Lo Re; Simona Talamanca; Valeria Terruso; Marco D'Amelio; Giovanni Savettieri
Journal:  Neurol Sci       Date:  2011-01-14       Impact factor: 3.307

4.  Unresponsive thrombotic thrombocytopenic purpura in critically ill adults.

Authors:  Eric Mariotte; Alice Blet; Lionel Galicier; Michael Darmon; Nathalie Parquet; Etienne Lengline; David Boutboul; Emmanuel Canet; Richard Traineau; Benoît Schlemmer; Agnès Veyradier; Elie Azoulay
Journal:  Intensive Care Med       Date:  2013-04-03       Impact factor: 17.440

5.  Rituximab in a child with autoimmune thrombotic thrombocytopenic purpura refractory to plasma exchange.

Authors:  Parameswaran Narayanan; Aparna Jayaraman; Rashi S Rustagi; S Mahadevan; Sreejith Parameswaran
Journal:  Int J Hematol       Date:  2012-05-03       Impact factor: 2.490

6.  Idiopathic combined, autoantibody-mediated ADAMTS-13/factor H deficiency in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in a 17-year-old woman: a case report.

Authors:  Daniel Patschan; Peter Korsten; Arne Behlau; Radovan Vasko; Malte Heeg; Nadera Sweiss; Gerhard A Müller; Michael Koziolek
Journal:  J Med Case Rep       Date:  2011-12-29

7.  Rituximab as first-line treatment for acquired thrombotic thrombocytopenic purpura.

Authors:  Haifei Chen; Ailin Fu; Jing Wang; Tianqin Wu; Zhengyang Li; Jieqing Tang; Hongshi Shen; Jingjing Zhu; Jie Li; Qian Zhu; Longmei Qing
Journal:  J Int Med Res       Date:  2017-03-21       Impact factor: 1.671

Review 8.  Rituximab in kidney disease and transplant.

Authors:  Kajal Chauhan; Anita A Mehta
Journal:  Animal Model Exp Med       Date:  2019-03-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.